Latest research into retatruptide peptide demonstrate significant outlook for managing obesity and type 2 disease. The peptide, a dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, seems to provide improved body mass and blood sugar control versus existing m